Effects of Epidermal Growth Factor on Glycolysis in A431 Cells
Overview
Affiliations
A431 cells were treated with epidermal growth factor (EGF) to study the mechanism by which this factor accelerates the glycolytic flux. After EGF treatment, fructose-2,6-bisphosphate (Fru-2,6-P2) levels rose up to 2-fold. This change correlated with an increase in phosphofructokinase-2 activity, which was not due to a change in the transcription or translation of the enzyme, neither in the amount of enzyme. PK-C does not appear to be involved in the signalling mechanism since EGF was equally potent in PK-C depleted cells than in control cells. The increase in Fru-2,6-P2 levels was lower and more transient in cells treated with EGF in a calcium-free medium than in the presence of the cation, and it was restored by the addition of calcium to the medium. These results suggest a possible role for calcium-mediated pathways in the control of Fru-2,6-P2 levels in A431 cells.
Eye on the horizon: The metabolic landscape of the RPE in aging and disease.
Hansman D, Du J, Casson R, Peet D Prog Retin Eye Res. 2024; 104:101306.
PMID: 39433211 PMC: 11833275. DOI: 10.1016/j.preteyeres.2024.101306.
Waye A, Ticiani E, Sharmin Z, Perez Silos V, Perera T, Tu A Chemosphere. 2024; 364:143301.
PMID: 39251161 PMC: 11540307. DOI: 10.1016/j.chemosphere.2024.143301.
Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands.
Zhao M, Jung Y, Jiang Z, Svensson K Front Physiol. 2020; 11:354.
PMID: 32372975 PMC: 7186430. DOI: 10.3389/fphys.2020.00354.
Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy.
Concha-Benavente F, Ferris R Front Pharmacol. 2017; 8:332.
PMID: 28611673 PMC: 5447743. DOI: 10.3389/fphar.2017.00332.
Xu Q, Zhang Q, Ishida Y, Hajjar S, Tang X, Shi H Oncotarget. 2016; 8(6):9557-9571.
PMID: 27926487 PMC: 5354753. DOI: 10.18632/oncotarget.13771.